Bukwang Pharmaceutical announced on December 17 that the phase II clinical trials of its diabetic drug MLR-1023 has ended.
This was phase II clinical trials carried out on 400 patients with type 2 diabetes through 40 sites in the US and 21 in Korea, totaling up to 61 sites, and it completely finished on the 14th, Eastern Time.
The phase II clinical trial began in August 2017, 400 patients were recruited in August 2018, drug administration was completed at the end of November, and it was finalized on December 14 after the observation period.
This process proves that Bukwang Pharmaceutical had an ability to carry out the clinical progress and get results within a year and four months after starting the phase II clinical trial.
Key results of the clinical trials are expected to be available as early as January 2019, and the complete results will be announced in June 2019 through the American Diabetes Association.